Nutriband (NTRB) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nutriband (NTRB) has outperformed OKYO Pharma (OKYO) over the past year, losing 28.8% versus a loss of 37.9%. Nutriband is the larger company by market cap ($73.5 million vs $72.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTRB | OKYO |
|---|---|---|
| Share price | $6.05 | $1.39 |
| Market cap | $73.54M | $72.95M |
| 1-day change | -10.44% | -2.73% |
| YTD return | +33.26% | -32.85% |
| 1-year return | -28.82% | -37.95% |
| 5-year return | -11.15% | — |
| EPS (TTM) | $-0.53 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.19 | $3.20 |
| 52-week low | $2.80 | $1.27 |
| Distance from 52-week high | -34.13% | -56.56% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +147.93% | +499.28% |
| Average volume | 62.42K | 94.59K |
| Shares outstanding | 12.16M | 52.48M |
| Employees | — | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Nutriband
NTRB stock →Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States.
Healthcare · Biotechnology
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Healthcare · Biotechnology · 5 employees
NTRB vs OKYO FAQ
Which is bigger, Nutriband or OKYO Pharma?
Nutriband (NTRB) is larger, with a market capitalization of $73.54M compared with $72.95M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, NTRB or OKYO?
NTRB returned -28.82% over the past 12 months, compared with -37.95% for OKYO (price return, excluding dividends). Past performance does not predict future results.
Are Nutriband and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.